Company / Operating Income
Revolution Medicines, Inc. Operating Income History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$1.2B
FY2025
5-year range
-$1.2B / -$54.1M
FY2021-FY2025
Trend
-71.5%
vs FY2024
Sector context
#200 of 204
Health Care
What the data says
Among 204 Health Care companies, Revolution Medicines, Inc. is in the bottom 2% for operating income. Operating Income has declined for 5 consecutive years, from -$40M in FY2020 to -$1.2B in FY2025.
Based on SEC 10-K filings.
-$1.2B in FY2025.
Declined from -$487M to -$1.2B over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 2% in Health CareTop 98% of 204This company -$1.2B Sector average $107.8M
▼
-1197.3% below sector average
Key checks
Key Insights
- Revolution Medicines, Inc.'s operating income has declined for 5 consecutive years.
- In FY2025, operating income decreased 71.5% year-over-year.
- Ranks #200 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -1.10 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$1.2B | -71.5% |
| FY2024 | -$689.5M | -41.5% |
| FY2023 | -$487.2M | -340.1% |
| FY2022 | -$110.7M | -104.5% |
| FY2021 | -$54.1M | -34.2% |
| FY2020 | -$40.3M | +25.5% |
| FY2019 | -$54.1M | -34.2% |
| FY2018 | -$40.3M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026